A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol [SUBSTUDY OF 700216591]

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Acronyms ADAPT-HER2+HR-

Most Recent Events

13 Nov 2024 Status changed from recruiting to active, no longer recruiting.
13 Nov 2024 Planned primary completion Date changed from 1 Aug 2015 to 1 Jan 2025.
13 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight